Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 9.6% in July

Avalo Therapeutics, Inc. (NASDAQ:AVTX) saw a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 58,600 shares, a decrease of 9.6% from the July 15th total of 64,800 shares. Based on an average daily trading volume, of 19,800 shares, the days-to-cover ratio is currently 3.0 days. Approximately 6.0% of the shares of the company are short sold.

Hedge Funds Weigh In On Avalo Therapeutics

An institutional investor recently bought a new position in Avalo Therapeutics stock. Affinity Asset Advisors LLC purchased a new position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $218,000. Affinity Asset Advisors LLC owned 0.97% of Avalo Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Trading Down 2.5 %

Shares of Avalo Therapeutics stock traded down $0.23 during trading on Friday, hitting $9.07. 10,815 shares of the company’s stock were exchanged, compared to its average volume of 286,616. Avalo Therapeutics has a 52-week low of $3.95 and a 52-week high of $71.04. The business has a 50-day simple moving average of $11.70 and a 200-day simple moving average of $10.34.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Monday, August 12th. The company reported ($14.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.70) by ($7.37). Avalo Therapeutics had a negative net margin of 1,639.50% and a negative return on equity of 1,439.87%. Equities research analysts predict that Avalo Therapeutics will post -28.11 earnings per share for the current year.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.